If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about the risk of gastroparesis. Medical literature has long recognized that GLP-1 receptor agonists can slow gastric emptying, and recent FDA label updates provide additional context for clinicians and patients. This page explains the key prescribing information changes and what they mean for monitoring gastrointestinal symptoms.
Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can, in susceptible individuals, progress to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis often overlaps with common gastrointestinal adverse effects reported in Ozempic trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which may reflect the drug's effect on gastric motility.
Mechanistic pathways linking Ozempic to gastroparesis involve GLP-1 receptor activation in the gut, which delays gastric emptying by inhibiting antral contractions and stimulating pyloric tone. While this effect is intended to improve postprandial glucose control, prolonged or excessive slowing can lead to symptomatic gastroparesis. The label does not explicitly list gastroparesis as a warning, but the high rates of nausea, vomiting, and dyspepsia—symptoms that overlap with gastroparesis—suggest a potential risk. The label includes a warning for serious hypersensitivity reactions, such as anaphylaxis and angioedema, but does not address gastroparesis specifically (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap in warnings raises questions about the adequacy of risk communication to patients and prescribers.
For patients in California who developed gastroparesis after using Ozempic, settlement-related considerations depend on the statute of limitations. In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For product liability claims involving prescription drugs, the discovery rule applies: the clock starts when the plaintiff knows or has reason to know that the injury was caused by the drug. Given that gastroparesis symptoms may develop gradually and be initially attributed to other causes, the timeline between exposure and documented harm is critical. Patients who began Ozempic and later developed persistent nausea, vomiting, or abdominal bloating should seek medical evaluation to confirm gastroparesis via gastric emptying scintigraphy or other diagnostic tests. The date of diagnosis or the date when a healthcare provider links symptoms to Ozempic may trigger the statute of limitations. Delays in diagnosis could affect the filing deadline, so affected individuals should consult a California attorney promptly.
Risk anchors for settlement include the strength of evidence linking Ozempic to gastroparesis, the adequacy of warnings, and the severity of harm. The label's adverse reaction data show a clear dose-response relationship for gastrointestinal events, but the absence of a specific gastroparesis warning may support claims of inadequate warnings. Settlement amounts may vary based on medical costs, lost wages, pain and suffering, and the degree of permanent injury. Patients with documented gastroparesis requiring hospitalization, nutritional support, or surgical intervention may have stronger claims. The timeline between Ozempic initiation and symptom onset should be documented in medical records to establish causation. In summary, Ozempic's pharmacological effect on gastric emptying, combined with clinical trial data showing high rates of gastrointestinal adverse events, supports a plausible link to gastroparesis. The label does not explicitly warn about this risk, which may be relevant for legal claims. California's statute of limitations requires prompt action after discovery of the injury. Affected patients should gather medical records, document symptom onset and Ozempic use, and seek legal advice to preserve their rights. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In California, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. For product liability claims involving prescription drugs, the discovery rule applies, meaning the clock starts when the plaintiff knows or has reason to know that the injury was caused by the drug. It is crucial to consult a California attorney promptly to preserve your rights.
The Ozempic label does not explicitly list gastroparesis as a warning. It includes warnings for serious hypersensitivity reactions such as anaphylaxis and angioedema, but does not address gastroparesis specifically (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, clinical trial data show high rates of gastrointestinal adverse events, including nausea, vomiting, and dyspepsia, which overlap with gastroparesis symptoms.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Ozempic exposure and a related diagnosis may request an independent, no-cost eligibility review.